Close
Achema

Covaxin likely to be available in first quarter of 2021: Bharat Biotech

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Green List by FDA to Cut Illegal GLP-1 Active Ingredients

The U.S. Food and Drug Administration has gone on...

As companies across the globe are speeding up to bring an effective COVID vaccine, Bharat Biotech’s Joint Managing Director Suchitra Ella hinted that India’s indigenous Covaxin in the country is likely to be available in the first quarter of next year. “We hope that with safety and efficacy data, Covaxin will be available in the first quarter of next year to the categories & the first responders according to the plan that government of India is embarking upon for phased vaccination,” said Suchitra Ella.

64 Diplomats visit Bharat Biotech

On Wednesday, 64 diplomats visited the premises of Hyderabad-based Bharat Biotech which is to produce COVID vaccine Covaxin. During the visit, Bharat Biotech’s Chairman and Managing Director Dr Krishna Ella delivered a presentation to explain the country’s vaccine manufacturing capabilities. Dr Ella informed the Foreign Heads of Mission that nearly 33% of global vaccines are produced in Hyderabad’s Genome Valley.

Meanwhile, an expert committee of the Central Drugs Standard Control Organisation (CDSCO) has sought additional safety and efficacy data for COVID-19 vaccine candidates Bharat Biotech and Serum Institute of India (SII). The Bharat Biotech inspection is scheduled to be followed by visits to similar facilities in other cities in due course of time.

Latest stories

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Green List by FDA to Cut Illegal GLP-1 Active Ingredients

The U.S. Food and Drug Administration has gone on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back